214 related articles for article (PubMed ID: 23190017)
1. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.
Martin P; Cheung SY; Yen M; Han D; Gillen M
Eur J Clin Pharmacol; 2016 Jan; 72(1):61-71. PubMed ID: 26490353
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Maringwa J; Kågedal M; Hamrén UW; Martin P; Cox E; Hamrén B
J Clin Pharmacol; 2015 Mar; 55(3):328-35. PubMed ID: 25280085
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
5. Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Boström E; Öhrn F; Hanze E; Sandström M; Martin P; Wählby-Hamrén U
J Clin Pharmacol; 2014 Dec; 54(12):1337-46. PubMed ID: 24895144
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Martin P; Oliver S; Gillen M; Marbury T; Millson D
Clin Ther; 2015 Dec; 37(12):2823-36. PubMed ID: 26519231
[TBL] [Abstract][Full Text] [Related]
7. The status of fostamatinib in the treatment of rheumatoid arthritis.
Morales-Torres J
Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
[TBL] [Abstract][Full Text] [Related]
8. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Scott DL
Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
[TBL] [Abstract][Full Text] [Related]
9. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Baluom M; Samara E; Grossbard EB; Lau DT
J Clin Pharmacol; 2011 Sep; 51(9):1310-8. PubMed ID: 21209239
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.
Pritchard EM; Stewart E; Zhu F; Bradley C; Griffiths L; Yang L; Suryadevara PK; Zhang J; Freeman BB; Guy RK; Dyer MA
Pharm Res; 2014 Nov; 31(11):3060-72. PubMed ID: 24906597
[TBL] [Abstract][Full Text] [Related]
11. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Elsby R; Baluom M; Lau D; Mant T
Clin Ther; 2015 Dec; 37(12):2811-22. PubMed ID: 26514315
[TBL] [Abstract][Full Text] [Related]
12. The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.
Platt AM; Benson RA; McQueenie R; Butcher JP; Braddock M; Brewer JM; McInnes IB; Garside P
Rheumatology (Oxford); 2015 Jan; 54(1):169-77. PubMed ID: 25065010
[TBL] [Abstract][Full Text] [Related]
13. Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.
Flanagan T; Martin P; Gillen M; Mathews D; Lisbon E; Kruusmägi M
Eur J Clin Pharmacol; 2017 Feb; 73(2):185-195. PubMed ID: 27858108
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
15. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
Sweeny DJ; Li W; Clough J; Bhamidipati S; Singh R; Park G; Baluom M; Grossbard E; Lau DT
Drug Metab Dispos; 2010 Jul; 38(7):1166-76. PubMed ID: 20371637
[TBL] [Abstract][Full Text] [Related]
17. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey.
Sweeny DJ; Li W; Grossbard E; Lau DT
Xenobiotica; 2010 Jun; 40(6):415-23. PubMed ID: 20415544
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
19. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
20. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
